[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

May 2017 | 280 pages | ID: O241845046BEN
GlobalData

US$ 10,995.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

Summary

Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, at which point the prognosis is poor. Current standard of care therapies focus on debulking surgery and platinum-based chemotherapy, with carboplatin and paclitaxel being the gold standard. The majority of patients respond well to initial first-line therapy and enter into remission, however over 80% of patients will relapse and require multiple lines of therapy.

For many years the ovarian cancer drug market has been fairly stagnant, mainly due to the high use of generics and the lack of successful development of new innovative therapies. However, with the recent approvals of Avastin and the PARP inhibitors Lynparza (olaparib), Rubraca (rucaparib), and Zejula (niraparib), the market is beginning to diversify. New understanding of the heterogeneity and biology of ovarian cancer has led to the active development of new targeted therapies, immuno-oncology (IO) drugs, and next-generation chemotherapies. A greater understanding of the tumor microenvironment is expected to occur over the forecast period, which is anticipated to further drive the successful development of new patient-specific therapies. GlobalData is predicting a total of 9 new entrants to launch over the forecast period from 2015-2025. Competition will be particularly fierce amongst PARP inhibitors as they continue to establish their place in the treatment paradigm of ovarian cancer.

Key Questions Answered
  • How will the ovarian cancer market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) change from 2015-2025?
  • What are the most promising late-stage pipeline drugs in ovarian cancer?
  • How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
  • What are the unmet needs in ovarian cancer treatment management?
  • What drivers and barriers will affect ovarian cancer therapeutics sales in the 7MM over the forecast period?
Scope
  • Overview of ovarian cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline ovarian cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting ovarian cancer therapeutics sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the 7MM ovarian cancer therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 7MM ovarian cancer therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ovarian cancer therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
1 TABLE OF CONTENTS

1.1 LIST OF TABLES
1.2 LIST OF FIGURES

2 OVARIAN CANCER: EXECUTIVE SUMMARY

2.1 Dramatic Growth, Driven by the Establishment of Standard of Care Maintenance Therapies, Is Projected for the 7MM Ovarian Cancer Market from 2015 to 2025
2.2 AstraZeneca, Tesaro, and Clovis are Poised for a Showdown in the PARP Inhibitor Ovarian Cancer Treatment Market for BRCA+, BRCA-like, and All Comers
2.3 Roche Expected to Remain Market Leader on the Heels of Avastin-based Combinations and the 7MM’s Second Programmed Death-Ligand 1 Inhibitor, Tecentriq, to Compete with Merck KGaA/Pfizer’s First-to-Market Bavencio
2.4 Unmet Need of More Therapies for Recurrent Patients in Later Lines of Therapy, Especially Platinum-Resistant Patients, Anticipated to be Partially Fulfilled, with Opportunities Remaining
2.5 What Do Physicians Think?

3 INTRODUCTION

3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4 DISEASE OVERVIEW

4.1 Etiology and Pathophysiology
4.2 Staging Systems
4.3 Risk Factors, Symptoms, and Screening
4.4 Prognosis and Quality of Life

5 EPIDEMIOLOGY

5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global Trends
  5.3.1 7MM Incidence Trends
  5.3.2 7MM Trends in Relative Survival
5.4 Forecast Methodology
  5.4.1 Sources Used Tables
  5.4.2 Forecast Assumptions and Methods
  5.4.3 Sources Not Used
5.5 Epidemiological Forecast for Ovarian Cancer (2015-2025)
  5.5.1 Diagnosed Incident Cases of Ovarian Cancer
  5.5.2 Age-Specific Diagnosed Incident Cases of Ovarian Cancer
  5.5.3 Age-Standardized Diagnosed Incidence of Ovarian Cancer
  5.5.4 Diagnosed Incident Cases of Primary Peritoneal Cancer
  5.5.5 Five-Year Diagnosed Prevalent Cases of Ovarian Cancer and Primary Peritoneal Cancer
5.6 Discussion
  5.6.1 Epidemiological Forecast Insight
  5.6.2 Limitations of the Analysis
  5.6.3 Strengths of the Analysis

6 CURRENT TREATMENT OPTIONS

6.1 Overview
6.2 Diagnosis and Treatment
  6.2.1 Diagnosis
  6.2.2 Treatment Guidelines
6.3 Clinical Practice and Leading Prescribed Drugs
6.4 Product Profiles - Major Brands, Angiogenesis Inhibitors
  6.4.1 Avastin (bevacizumab)
6.5 Product Profiles - Major Brands, PARP Inhibitors
  6.5.1 Lynparza (olaparib)
  6.5.2 Rubraca (rucaparib)
  6.5.3 Zejula (niraparib)
6.6 Product Profiles - Major Brands, Next-Generation Chemotherapies
  6.6.1 Yondelis (trabectedin)
6.7 Generic Chemotherapy
  6.7.1 Front-Line Treatment (Adjuvant/First Line)
  6.7.2 Recurrent Disease

7 UNMET NEEDS ASSESSMENT AND OPPORTUNITY ANALYSIS

7.1 Overview
7.2 Improved First-line Therapies
  7.2.1 Unmet Need
  7.2.2 Gap Analysis
  7.2.3 Opportunity
7.3 Alternative Treatment Options for Platinum-Refractory/Resistant Patients
  7.3.1 Unmet Need
  7.3.2 Gap Analysis
  7.3.3 Opportunity
7.4 Individualized Treatment Approaches
  7.4.1 Unmet Need
  7.4.2 Gap Analysis
  7.4.3 Opportunity
7.5 Therapy Option for Histological Subtypes Beyond High-Grade Serous Ovarian Cancer
  7.5.1 Unmet Need
  7.5.2 Gap Analysis
  7.5.3 Opportunity
7.6 An Early Stage Diagnostic for Ovarian Cancer
  7.6.1 Unmet Need
  7.6.2 Gap Analysis
  7.6.3 Opportunity

8 RESEARCH AND DEVELOPMENT STRATEGIES

8.1 Overview
  8.1.1 Optimizing Chemotherapy
  8.1.2 Targeted Therapies - A Patient Specific Approach
  8.1.3 Immunotherapies - A Patient Specific Approach
  8.1.4 Combination Therapies
  8.1.5 Licenses and Alliances
8.2 Clinical Trial Design
  8.2.1 Current Clinical Trial Endpoints
  8.2.2 The Future of Clinical Trial Endpoints
  8.2.3 Moving Beyond the Current Platinum Sensitive/Resistant Paradigm for Patient Recruitment in Recurrent Clinical Trials

9 PIPELINE ASSESSMENT

9.1 Overview
9.2 Product Profiles - Immune Checkpoint Modulators
  9.2.1 Bavencio (avelumab)
  9.2.2 Opdivo (nivolumab)
  9.2.3 Tecentriq (atezolizumab)
9.3 Product Profiles - Cancer Vaccines
  9.3.1 Vigil (gemogenovatucel-T)
9.4 Product Profiles - Vascular Disrupting Agents
  9.4.1 Fosbretabulin tromethamine
9.5 Product Profiles - PARP Inhibitors
  9.5.1 Veliparib
9.6 Product Profiles - Targeted Cytotoxic Therapies (Antibody-Drug Conjugates)
  9.6.1 Mirvetuximab soravtansine
9.7 Product Profiles - Next-Generation Chemotherapies
  9.7.1 Opaxio (paclitaxel poliglumex)
  9.7.2 Lurbinectedin
  9.7.3 Apealea/Paclical (paclitaxel)
9.8 Innovative Early Stage Approaches
  9.8.1 Immune Checkpoint Modulators
  9.8.2 Oncolytic Viruses
  9.8.3 Angiogenesis Inhibitors
  9.8.4 Interleukin-12 Agonists
  9.8.5 Toll-Like Receptor 8 Agonists
  9.8.6 Cancer Vaccines
  9.8.7 Kinase Inhibitors
  9.8.8 Targeted Cytotoxic Therapies
  9.8.9 P53 Agonists
9.9 Other Notable Drugs in Clinical Development

10 PIPELINE VALUATION ANALYSIS

10.1 Clinical Benchmark of Key Pipeline Products
10.2 Commercial Benchmark of Key Pipeline Therapies
10.3 Competitive Assessment
10.4 Top-Line Ten-Year Forecast
  10.4.1 US
  10.4.2 5EU
  10.4.3 Japan

11 APPENDIX

11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
  11.4.1 Percentage of Drug-Treated Patients
  11.4.2 Drugs Included in Each Therapeutic Class
  11.4.3 Launch and Patent Expiry Dates
  11.4.4 General Pricing Assumptions
  11.4.5 Average Body Weight and Surface Area Across the 7MM
  11.4.6 General Forecast Assumptions
  11.4.7 Individual Drug Assumptions
  11.4.8 Generic and Biosimilar Erosion
  11.4.9 Pricing of Pipeline Agents
11.5 Primary Research
  11.5.1 Physicians and Specialists Included in This Study
  11.5.2 Online Survey of High-Prescribing Physicians
11.6 About the Authors
  11.6.1 Analysts
  11.6.2 Epidemiologist
  11.6.3 Therapy Area Director
  11.6.4 Global Director of Therapy Analysis and Epidemiology
  11.6.5 Global Head of Healthcare
11.7 About GlobalData
11.8 Contact Us
11.9 Disclaimer 280

LIST OF TABLES

Table 1: Ovarian Cancer: Key Metrics in the 7MM
Table 2: FIGO Guidelines: Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum
Table 3: FDA Recommendations for Screening Tests for Women and Physicians, 2016
Table 4: Risk Factors of OC
Table 5: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of OC and PPC
Table 6: 7MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of OC and PPC
Table 7: 7MM, Diagnosed Incident Cases of OC, Ages ?18 Years, N, 2015-2025
Table 8: 7MM, Age-Specific Diagnosed Incident Cases of OC, N (Row %), 2015
Table 9: 7MM, Diagnosed Incident Cases of PPC, Ages ?18 Years, N, 2015-2025
Table 10: 7MM, Five-Year Diagnosed Prevalent Cases of OC and PPC, Ages ?18 Years, N, 2015-2025
Table 11: Treatment Guidelines for Ovarian Cancer in the 7MM
Table 12: Preferred Single Agents or Combinations and Other Potentially Active Agents for Ovarian Cancer, by Platinum-Sensitive or Platinum-Resistant Disease
Table 13: Product Profile - Avastin
Table 14: Top-Line Data Summary for the Pivotal Phase II Trials of Avastin in Ovarian Cancer
Table 15: Avastin Safety Data from GOG-0218 Study in Newly Diagnosed Ovarian Cancer
Table 16: Grade 3 or 4 AEs from GOG-0213 Study in Recurrent Platinum-Sensitive Ovarian Cancer
Table 17: Grade ?3 AEs from AURELIA Study in Recurrent Platinum-Resistant Ovarian Cancer
Table 18: Avastin SWOT Analysis in Ovarian Cancer, 2017
Table 19: Product Profile - Lynparza
Table 20: Efficacy Data for Lynparza Tablets from SOLO2 Trial
Table 21: Efficacy Data of Lynparza from Phase III Trial in BRCA-mutated Advanced Ovarian Cancer
Table 22: Efficacy Data of Lynparza from Study 19 in Platinum-Sensitive Recurrent BRCA+ Ovarian Cancer
Table 23: Most Commonly Reported AEs, Occurring in at Least 15% of Patients in Study 19
Table 24: Lynparza SWOT Analysis in Ovarian Cancer, 2017
Table 25: Product Profile - Rubraca
Table 26: Pooled Efficacy Data of Rubraca from Study 10 and ARIEL2 in BRCA+ Ovarian Cancer
Table 27: Most Common AEs Reported in ?20% of Patients in Study 10 and ARIEL2
Table 28: Rubraca SWOT Analysis in Ovarian Cancer, 2017
Table 29: Product Profile - Zejula
Table 30: Efficacy Data of Zejula from NOVA Study in Platinum-Sensitive Ovarian Cancer
Table 31: Summary of the Main Reported AEs in Ovarian Cancer Patients Treated with Zejula
Table 32: Zejula SWOT Analysis, Ovarian Cancer 2017
Table 33: Product Profile - Yondelis
Table 34: Efficacy Data of Yondelis from OVA-301 in Ovarian Cancer
Table 35: Most Commonly Reported Grade 3 and 4 AEs in ?5% of Patients in OVA-301
Table 36: Yondelis SWOT Analysis in Ovarian Cancer, 2017
Table 37: Key Clinical Trials for Generic Chemotherapies in the Front-Line Setting in Ovarian Cancer
Table 38: Key Clinical Trials for Generic IP Chemotherapies in the Front-Line Setting in Ovarian Cancer
Table 39: Key Clinical Trials for Dose-Dense Chemotherapy in Ovarian Cancer
Table 40: Key Clinical Trials for Ovarian Cancer Neoadjuvant Chemotherapy Treatment
Table 41: Key Clinical Trials for Chemotherapy Combinations in Platinum-Sensitive Ovarian Cancer
Table 42: Unmet Needs and Opportunities in Ovarian Cancer
Table 43 provides an overview of the key Phase II and III clinical trials being conducted in ovarian cancer.
Table 44: Potential New Classification System for Recurrent Ovarian Cancer
Table 45: Promising Products in Clinical Development for Ovarian Cancer, 2017
Table 46: Product Profile - Bavencio
Table 47: Efficacy Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2016
Table 48: Efficacy Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2015
Table 49: Efficacy Expansion Cohort Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2015
Table 50: Safety Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2016
Table 51: Bavencio SWOT Analysis, Ovarian Cancer 2017
Table 52: Product Profile - Opdivo
Table 53: Efficacy Data for Opdivo in Platinum-Resistant Ovarian Cancer (UMIN000005714)
Table 54: Treatment-Related AEs of Special Interest in Ovarian Cancer Patients Treated with Opdivo
Table 55: Opdivo SWOT Analysis, Ovarian Cancer 2017
Table 56: Product Profile - Tecentriq
Table 57: Tecentriq SWOT Analysis, Ovarian Cancer 2017
Table 58: Product Profile - Vigil (gemogenovatucel-T)
Table 59: Efficacy Data for Vigil in Ovarian Cancer from its Ongoing Phase II Trial
Table 60: Efficacy and Response Data from a Pooled Data Analysis of Six Vigil Clinical Trials
Table 61: Vigil SWOT Analysis, Ovarian Cancer 2017
Table 62: Product Profile - Fosbretabulin Tromethamine
Table 63: Efficacy Data of GOG-01861 Trial of Fosbretabulin in Ovarian Cancer
Table 64: Grade ?2 AEs Experienced During GOG-01861 in Recurrent Ovarian Cancer
Table 65: Fosbretabulin SWOT Analysis, Ovarian Cancer 2017
Table 66: Product Profile - Veliparib
Table 67: Top-Line Data Summary for the Pivotal Phase II Trials of Avastin in Ovarian Cancer
Table 68: AEs Associated with Veliparib in GOG-0280 Clinical Trial
Table 69: Veliparib SWOT Analysis, Ovarian Cancer 2017
Table 70: Product Profile - Mirvetuximab soravtansine
Table 71: Efficacy Data from Phase I Study of Mirvetuximab Soravtansine in FR?+ Ovarian Cancer
Table 72: Safety Data from Phase I Study of Mirvetuximab Soravtansine in FR?+ Ovarian Cancer
Table 73: Mirvetuximab Soravtansine SWOT Analysis, Ovarian Cancer 2017
Table 74: Product Profile - Opaxio
Table 75: Efficacy Data from GOG-0186C Study in Heavily Pretreated Ovarian Cancer
Table 76: Treatment Related AEs for Opaxio from GOG-0186C in Ovarian Cancer
Table 77: Opaxio SWOT Analysis, Ovarian Cancer 2017
Table 78: Product Profile - Lurbinectedin
Table 79: Efficacy Data from Phase II Trial of Lurbinectedin in Platinum-Resistant/Refractory Ovarian Cancer
Table 80: Lurbinectedin Treatment in Related AEs in Platinum-Resistant/Refractory Ovarian Cancer
Table 81: Lurbinectedin SWOT Analysis, Ovarian Cancer 2017
Table 82: Product Profile - Apealea
Table 83: Efficacy Data from Phase III Study of Apealea in Platinum-Sensitive Ovarian Cancer
Table 84: All Grade AEs Associated with Apealea in Platinum-Sensitive Ovarian Cancer
Table 85: Apealea SWOT Analysis, Ovarian Cancer 2017
Table 86: Other Innovative Approaches to Ovarian Cancer Management, 2017
Table 87: Ovarian Cancer-Specific Clinical Trials Involving Yervoy
Table 88: Ovarian Cancer-Specific Clinical Trials Involving Keytruda
Table 89: Ovarian Cancer-Specific Clinical Trials Involving Monalizumab
Table 90: Ovarian Cancer-Specific Clinical Trials Involving Epacadostat
Table 91: Ovarian Cancer-Specific Clinical Trials Involving Durvalumab
Table 92: Ovarian Cancer-Specific Clinical Trials Involving Reolysin
Table 93: Ovarian Cancer-Specific Clinical Trials Involving Enadenotucirev
Table 94: Efficacy of Cediranib from ICON6 Study in Relapsed Platinum-Sensitive Ovarian Cancer
Table 95: Summary of Grade ?3 AEs During ICON6 in Platinum-Sensitive Recurrent Ovarian Cancer
Table 96: Cediranib SWOT Analysis, Ovarian Cancer 2017
Table 97: Ovarian Cancer-Specific Clinical Trials Involving GEN-1
Table 98: Ovarian Cancer-Specific Clinical Trials Involving Motolimod
Table 99: Ovarian Cancer-Specific Clinical Trials Involving CVac
Table 100: Ovarian Cancer-Specific Clinical Trials Involving DCVAC/OvCa
Table 101: Ovarian Cancer-Specific Clinical Trials Involving DPX-Survivac
Table 102: Ovarian Cancer-Specific Clinical Trials Involving Binimetinib
Table 103: Ovarian Cancer-Specific Clinical Trials Involving Vargatef
Table 104: Ovarian Cancer-Specific Clinical Trials Involving Masitinib
Table 105: Ovarian Cancer-Specific Clinical Trials Involving Acalabrutinib
Table 106: Ovarian Cancer-Specific Clinical Trials Involving IMAB-027
Table 107: Ovarian Cancer-Specific Clinical Trials Involving APR-246
Table 108: Other Notable Ovarian Cancer Products in Development, 2017
Table 109: Clinical Benchmarking of Key Marketed and Pipeline Products
Table 110: Clinical Benchmarking of Key Marketed and Pipeline Products, Continued
Table 111: Commercial Benchmarking of Key Marketed and Pipeline Products
Table 112: Commercial Benchmarking of Key Marketed and Pipeline Products, Continued
Table 113: Top-Line Sales Forecasts for Ovarian Cancer Products, 2015-2025 ($M)
Table 114: Key Events Impacting Sales for Ovarian Cancer Products, 2015-2025
Table 115: Ovarian Cancer Products Market - Drivers and Barriers, 2015-2025
Table 116: Ovarian Cancer Patient Population segmentations in the 7MM - Secondary Sources Leveraged
Table 117: Ovarian Cancer Marketed and Pipeline Products by Therapeutic Class
Table 118: Historical and Projected Launch Dates for Key Drugs in Ovarian Cancer Across the 7MM
Table 119: Patent Expiry Dates of Key Drugs in Ovarian Cancer Across the 7MM
Table 120: Average Body Weight and Surface Area Across the 7MM
Table 121: Average Cost of Therapy of Avastin in the 7MM
Table 122: Average Cost of Therapy of Lynparza in the 7MM
Table 123: Average Cost of Therapy of Rubraca in the US and 5EU
Table 124: Average Cost of Therapy of Yondelis in the 7MM
Table 125: Average Cost of Therapy of Votrient in the 7MM
Table 126: Average Cost of Therapy of Zejula in the US and 5EU
Table 127: Average Cost of Therapy of Veliparib in the 7MM
Table 128: Average Cost of Therapy of Bavencio in the 7MM
Table 129: Average Cost of Therapy of Tecentriq in the 7MM
Table 130: Average Cost of Therapy of Opdivo in the 7MM
Table 131: Average Cost of Therapy of Vigil in the 7MM
Table 132: Average Cost of Therapy of Lurbinectedin in the 7MM
Table 133: Average Cost of Therapy of Fosbretabulin in the US and 5EU
Table 134: Average Cost of Therapy of Mirvetuximab Soravtansine in the 7MM
Table 135: Average Cost of Therapy of Apealea in the US and 5EU
Table 136: High-Prescribing Physicians Surveyed, by Country 277

LIST OF FIGURES

Figure 1: 7MM Sales from Therapeutic Agents by Region, 2015 and 2025
Figure 2: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017
Figure 3: Selected Types of Ovarian Cancer and Other Closely Related Neoplasms
Figure 4: Risk Factors and Symptoms Suggestive of Ovarian Cancer
Figure 5: 7MM, Diagnosed Incidence Rate of OC, Cases per 100,000, All Ages, Women, 1998?2007
Figure 6: 7MM, Diagnosed Incident Cases of OC, Ages ?18 Years, N, 2015-2025
Figure 7: 7MM, Age-Specific Diagnosed Incident Cases of OC, N (Row %), 2015
Figure 8: 7MM, Age-Standardized Diagnosed Incidence of OC, Ages?18 Years, Cases per 100,000, 2015
Figure 9: 7MM, Diagnosed Incident Cases of PPC, Ages ?18 Years, N, 2015-2025
Figure 10: 7MM, Five-Year Diagnosed Prevalent Cases of OC and PPC, Ages ?18 Years, N, 2015-2025
Figure 11: Top-Level Treatment Flow Chart for Ovarian Cancer Patients
Figure 12: Clinical Development Program for Avastin in Ovarian Cancer
Figure 13: Clinical Development Program for Lynparza in Ovarian Cancer
Figure 14: Clinical Development Program for Rubraca in Ovarian Cancer
Figure 15: Clinical Devlopment Program for Zejula in Ovarian Cancer
Figure 16: Clinical Development Program for Yondelis in Ovarian Cancer
Figure 17: Clinical Development Program for Bavencio in Ovarian Cancer
Figure 18: Clinical Development Program for Opdivo in Ovarian Cancer
Figure 19: Clinical Development Program for Tecentriq in Ovarian Cancer
Figure 20: Clinical Development Program for Vigil in Ovarian Cancer
Figure 21: Clinical Development Program for Fosbretabulin in Ovarian Cancer
Figure 22: Clinical Development Program for Veliparib in Ovarian Cancer
Figure 23: Clinical Development Program for Mirvetuximab Soravtansine in Ovarian Cancer
Figure 24: Clinical Development Program for Opaxio in Ovarian Cancer
Figure 25: Clinical Development Program for Lurbinectedin in Ovarian Cancer
Figure 26: Clinical Development Program for Apealea in Ovarian Cancer
Figure 27: Clinical Development Program for Cediranib in Ovarian Cancer
Figure 28: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017
Figure 29: Sales for Ovarian Cancer Products by Region, 2015-2025


More Publications